Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Ligand Pharmaceuticals Incorporated

Vertex vs Ligand: A Decade of Cost Efficiency

__timestampLigand Pharmaceuticals IncorporatedVertex Pharmaceuticals Incorporated
Wednesday, January 1, 2014913600060987000
Thursday, January 1, 20155807000125542000
Friday, January 1, 20165571000210460000
Sunday, January 1, 20175366000275119000
Monday, January 1, 20186337000409539000
Tuesday, January 1, 201911347000547758000
Wednesday, January 1, 202030419000736300000
Friday, January 1, 202162176000904200000
Saturday, January 1, 2022528270001080300000
Sunday, January 1, 2023350490001262200000
Monday, January 1, 20241530500000
Loading chart...

Data in motion

Cost of Revenue Efficiency: A Tale of Two Pharmaceutical Giants

In the competitive world of pharmaceuticals, cost efficiency is a critical factor for success. Over the past decade, Vertex Pharmaceuticals Incorporated has consistently outperformed Ligand Pharmaceuticals Incorporated in terms of cost of revenue efficiency. From 2014 to 2023, Vertex's cost of revenue surged by over 1,900%, reaching a peak in 2023, while Ligand's growth was more modest, increasing by approximately 280% during the same period.

Vertex's strategic investments in research and development have paid off, allowing them to scale operations efficiently. In contrast, Ligand's cost of revenue, though growing, reflects a more conservative approach. This divergence highlights the varying strategies within the pharmaceutical industry, where innovation and cost management play pivotal roles. As we look to the future, these trends may offer insights into the evolving landscape of pharmaceutical giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025